Drug Trial Radar · NCT01659021
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Last checked: Nov 19, 2026Latest source record: Aug 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
261
Actual
Start
Dec 4, 2012
Primary completion
Aug 15, 2018
Study completion Aug 15, 2018
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
Conditions
- Chronic Lymphocytic Leukemia
Interventions
IdelalisibDrug
150 mg tablets administered orally twice daily
OfatumumabDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: Randomization to End of Study (up to 60 months)
Locations
80 sites in 11 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
California Cancer Associates for Research and Excellence (CCARE)
Fresno, California
Kaiser Permanente
San Diego, California
Coastal Integrative Cancer Care
San Luis Obispo, California
Stanford University Medical Center
Stanford, California
Kaiser Permanente Vallejo Medical Center
Vallejo, California
Kaiser Permanente of Colorado
Denver, Colorado
Saint Mary's Regional Cancer Center
Grand Junction, Colorado
Cancer Specialists of North Florida
Jacksonville, Florida
Georgia Regents University
Augusta, Georgia
Montgomery Cancer Center
Mount Sterling, Kentucky
Center for Cancer and Blood Disorders, PC
Bethesda, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Washington University Medical Center
St Louis, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Weill Cornell Medical Center
New York, New York
Oncology Hematology Care, Inc.
Cincinnati, Ohio
The Ohio State University Medical Center
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Upstate Oncology Associates
Greenville, South Carolina
Tennessee Oncology, PLLC
Chattanooga, Tennessee
Tenessee Oncology, PLLC
Nashville, Tennessee
Utah Cancer Specialists
Salt Lake City, Utah
Northwest Medical Specialties
Tacoma, Washington
Queen Elizabeth Hospital
Woodville, Australia
Saint George and Sutherland Hospitals
Kogarah, New South Wales, Australia
Prince of Wales Hospital
Randwick, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Haematology and Oncology Clinics of Australia at Mater
Milton, Queensland, Australia
Ashford Cancer Centre Research
Ashford, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Frankston Hospital
Melbourne, Victoria, Australia
Ziekenhuis Netwerk Antwerpen
Antwerp, Belgium
Cliniques Universitaires Saint Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitaire Ziekenhuis Gasthuisberg
Leuven, Belgium
Cancer Care Manitoba
Winnipeg, Canada
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.